Xiaomin Yu

Xiaomin Yu

Auto-generated profile, based on publicly available information

Xiaomin Yu

Liangzhu Laboratory, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in Nature
Verified
Journal Article
Closed access
PDF file
PTPanfeng Tao
Panfeng Tao
JSJinqiao Sun
Jinqiao Sun
ZWZheming Wu
Zheming Wu
SWShihao Wang
Shihao Wang
JWJun Wang
Jun Wang
QZQing Zhou
Qing Zhou

13 June 2023 in Immunity
Verified
Journal Article
Closed access
YWYusha Wang
Yusha Wang
JWJun Wang
Jun Wang
WZWenjie Zheng
Wenjie Zheng
JZJiahui Zhang
Jiahui Zhang
JWJinbo Wang
Jinbo Wang
QZQing Zhou
Qing Zhou

26 January 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JLJ.J. Lyons
J.J. Lyons
YLY. Liu
Y. Liu
CMC.A. Ma
C.A. Ma
XYX. Yu
X. Yu
MOM.P. O’cOnnell
M.P. O’cOnnell
JMJ.D. Milner
J.D. Milner
Nonimmunological connective tissue phenotypes in humans are common among some congenital and acquired allergic diseases. Several of these congenital disorders have been associated with either increased TGF-β activity or impaired STAT3 activation, suggesting that these pathways might intersect and that their disruption may contribute to atopy. In this study, we show that STAT3 negatively regulates TGF-β signaling via ERBB2-interacting protein (ERBIN), a SMAD anchor for receptor activation and SMAD2/3 binding protein. Individuals with dominant-negative STAT3 mutations (STAT3mut) or a loss-of-function mutation in ERBB2IP (ERBB2IPmut) have evidence of deregulated TGF-β signaling with increased regulatory T cells and total FOXP3 expression. These naturally occurring mutations, recapitulated in vitro, impair STAT3–ERBIN–SMAD2/3 complex formation and fail to constrain nuclear pSMAD2/3 in response to TGF-β. In turn, cell-intrinsic deregulation of TGF-β signaling is associated with increased functional IL-4Rα expression on naive lymphocytes and can induce expression and activation of the IL-4/IL-4Rα/GATA3 axis in vitro. These findings link increased TGF-β pathway activation in ERBB2IPmut and STAT3mut patient lymphocytes with increased T helper type 2 cytokine expression and elevated IgE.

2 June 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RWRuo-Ran Wang
Ruo-Ran Wang
XQXinyuan Qiu
Xinyuan Qiu
RPRan Pan
Ran Pan
HFHongxing Fu
Hongxing Fu
ZZZiyin Zhang
Ziyin Zhang
ZMZhuo-Xian Meng
Zhuo-Xian Meng
Pancreatic β cell plasticity is the primary determinant of disease progression and remission of type 2 diabetes (T2D). However, the dynamic nature of β cell adaptation remains elusive. Here, we establish a mouse model exhibiting the compensation-to-decompensation adaptation of β cell function in response to increasing duration of high-fat diet (HFD) feeding. Comprehensive islet functional and transcriptome analyses reveal a dynamic orchestration of transcriptional networks featuring temporal alteration of chromatin remodeling. Interestingly, prediabetic dietary intervention completely rescues β cell dysfunction, accompanied by a remarkable reversal of HFD-induced reprogramming of islet chromatin accessibility and transcriptome. Mechanistically, ATAC-based motif analysis identifies CTCF as the top candidate driving dietary intervention–induced preservation of β cell function. CTCF expression is markedly decreased in β cells from obese and diabetic mice and humans. Both dietary intervention and AAV-mediated restoration of CTCF expression ameliorate β cell dysfunction ex vivo and in vivo, through transducing the lipid toxicity and inflammatory signals to transcriptional reprogramming of genes critical for β cell glucose metabolism and stress response.

19 November 2021 in Science Advances
Verified
Journal Article
Open access
PTPanfeng Tao
Panfeng Tao
SWShihao Wang
Shihao Wang
SOSeza Ozen
Seza Ozen
PLPui Y. Lee
Pui Y. Lee
JZJiahui Zhang
Jiahui Zhang
QZQing Zhou
Qing Zhou
Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production.

10 January 2022 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
HDHongling Di
Hongling Di
JZJiahui Zhang
Jiahui Zhang
EGErzhi Gao
Erzhi Gao
CZChunxia Zheng
Chunxia Zheng
XHXianghua Huang
Xianghua Huang
ZLZhihong Liu
Zhihong Liu
Alport syndrome (AS) is an inherited type IV collagen–related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD). X-linked AS (XLAS) is caused by mutations in the COL4A5 gene. The aim of this study was to investigate the effects of underlying mutations on clinical manifestations and the response to therapy in XLAS. We conducted a retrospective cohort study of 187 Chinese male patients with XLAS confirmed by pathological examination and genetic analysis. The Kaplan–Meier method and Cox proportional hazards model were used to assess the age and risk of progression to ESRD under different genotypes and treatment conditions. A strong relationship between transcript type and renal outcome was observed, with the median age of ESRD onset being 22 years for truncating mutations and 39 years for non-truncating mutations. The response of affected patients to renin–angiotensin–aldosterone system (RAAS) blockers was genotype-associated. This therapy delayed the onset of ESRD by 16 years in patients with non-truncating mutations and 3 years in patients with truncating mutations. The efficacy of RAAS blockers functioned in a time-dependent manner, with a 7% reduction in the risk of progression to ESRD per each 6-month increase in treatment duration [hazard ratio 0.93 (95% confidence interval 0.89–0.96); P < 0.001]. Clinical features and response to RAAS blockers were observed to be strongly correlated with the genotypes of male XLAS patients. Genotyping of COL4A5 gene mutations is essential and is a useful tool to assess the prognosis of AS patients.